{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T04:23:01Z","timestamp":1768882981273,"version":"3.49.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T00:00:00Z","timestamp":1673481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T00:00:00Z","timestamp":1673481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation","doi-asserted-by":"crossref","award":["No.82000195"],"award-info":[{"award-number":["No.82000195"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation","doi-asserted-by":"crossref","award":["No.82070203"],"award-info":[{"award-number":["No.82070203"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation","doi-asserted-by":"crossref","award":["No.81770210"],"award-info":[{"award-number":["No.81770210"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007129","name":"Shandong Provincial Natural Science Foundation","doi-asserted-by":"crossref","award":["No. ZR2020QH094"],"award-info":[{"award-number":["No. ZR2020QH094"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Technology Development Project of Jinan City","award":["No.202019182"],"award-info":[{"award-number":["No.202019182"]}]},{"name":"Academic Promotion Programme of Shandong First Medical University","award":["No.2020RC007"],"award-info":[{"award-number":["No.2020RC007"]}]},{"name":"Academic Promotion Programme of Shandong First Medical University","award":["No.2019QL018"],"award-info":[{"award-number":["No.2019QL018"]}]},{"name":"Shandong Provincial Hospital Youth Talent Plan"},{"DOI":"10.13039\/100014103","name":"Key Research and Development Program of Shandong Province","doi-asserted-by":"crossref","award":["No.2018CXGC1213"],"award-info":[{"award-number":["No.2018CXGC1213"]}],"id":[{"id":"10.13039\/100014103","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Translational Research Grant of NCRCH","award":["No.2021WWB02"],"award-info":[{"award-number":["No.2021WWB02"]}]},{"name":"Translational Research Grant of NCRCH","award":["No.2020ZKMB01"],"award-info":[{"award-number":["No.2020ZKMB01"]}]},{"name":"Taishan Scholars Program of Shandong Province"},{"name":"Shandong Provincial Engineering Research Center of Lymphoma"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cytidine triphosphate synthase 2 (CTPS2) is an essential metabolic enzyme that catalyzes the biosynthesis of CTP. CTP synthases contribute to lymphocytes proliferation and tumorigenesis, but the role of CTPS2 in chronic lymphocytic leukemia (CLL) remains undefined.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In silico analysis was performed to quantified the expression and clinical analysis of CTPS2 and BRCA1. The expression was then validated on the internal sets. Loss-and gain-of-function assays were conducted to investigate the physiological phenotypes in CLL. RNA-seq was employed to probe the molecular mechanism of CTPS2.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Herein, significant elevated expression of CTPS2 was observed in CLL patients compared to normal CD19\u2009+\u2009B cells, which was verified in three independent cohorts. Furthermore, overexpression of CTPS2 was closely associated with undesired prognostic indicators, including unmutated IGHV status and chromosome 11q23 deletion. Additionally, elevated CTPS2 expression predicted adverse overall survival and treatment-free survival with independent prognostic significance. Downregulation of CTPS2 in CLL cells exhibited attenuated cell proliferation, arrested G2\/M cell cycle and increased apoptosis. The addition of CTP or glutamine could reverse the above effects. Since RNA-seq showed the enrichment in DNA damage and response signaling, we subsequently found that silence of CTPS2 remarkably elevated DNA damage and decreased DNA repair. It was demonstrated that CTPS2 mediated DNA damage response via interacting with Breast Cancer 1 (BRCA1) protein in CLL through CoIP assays and rescued experiments.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Collectively, our study generated the novel findings that CTPS2 promoted CLL progression via DNA damage response and repair pathway. Targeting nucleotide metabolism potentially became an attractive strategy for treatment against CLL.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40164-022-00364-0","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T06:03:03Z","timestamp":1673503383000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["CTP synthase 2 predicts inferior survival and mediates DNA damage response via interacting with BRCA1 in chronic lymphocytic leukemia"],"prefix":"10.1186","volume":"12","author":[{"given":"Xinting","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiarui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,12]]},"reference":[{"issue":"26","key":"364_CR1","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","volume":"35","author":"CJ Turtle","year":"2017","unstructured":"Turtle CJ, Hay KA, Hanafi LA, et al. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib. J Clin Oncol. 2017;35(26):3010\u201320.","journal-title":"J Clin Oncol"},{"issue":"1","key":"364_CR2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40164-022-00292-z","volume":"11","author":"Y Nie","year":"2022","unstructured":"Nie Y, Yun X, Zhang Y, et al. Targeting metabolic reprogramming in chronic lymphocytic leukemia. Exp Hematol Oncol. 2022;11(1):39.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"364_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40880-018-0300-5","volume":"38","author":"Y Qin","year":"2018","unstructured":"Qin Y, Song Y, Shen Z, et al. Safety and efficacy of obinutuzumab in Chinese patients with B-cell lymphomas: a secondary analysis of the GERSHWIN trial. Cancer Commun. 2018;38(1):31.","journal-title":"Cancer Commun"},{"issue":"1","key":"364_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40164-022-00283-0","volume":"11","author":"Y Xu","year":"2022","unstructured":"Xu Y, Ye H. Progress in understanding the mechanisms of resistance to BCL-2 inhibitors. Exp Hematol Oncol. 2022;11(1):31.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"364_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40364-022-00357-5","volume":"10","author":"J Zhang","year":"2022","unstructured":"Zhang J, Lu X, Li J, et al. Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma. Biomarker Res. 2022;10(1):17.","journal-title":"Biomarker Res"},{"key":"364_CR6","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40364-020-00222-3","volume":"8","author":"X Yun","year":"2020","unstructured":"Yun X, Zhang Y, Wang X. Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia. Biomarker Res. 2020;8:40.","journal-title":"Biomarker Res"},{"issue":"3","key":"364_CR7","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41375-018-0366-8","volume":"33","author":"PH Nguyen","year":"2019","unstructured":"Nguyen PH, Niesen E, Hallek M. New roles for B cell receptor associated kinases: when the B cell is not the target. Leukemia. 2019;33(3):576\u201387.","journal-title":"Leukemia"},{"issue":"1","key":"364_CR8","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13045-022-01335-y","volume":"15","author":"Y Wang","year":"2022","unstructured":"Wang Y, Johnson KCC, Gatti-Mays ME, et al. Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy. J Hematol Oncol. 2022;15(1):118.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"364_CR9","doi-asserted-by":"publisher","first-page":"e0153021","DOI":"10.1128\/mBio.01530-21","volume":"12","author":"JH Liang","year":"2021","unstructured":"Liang JH, Wang C, Yiu SPT, et al. Epstein-Barr virus induced cytidine metabolism roles in transformed B-cell growth and survival. mBio. 2021;12(4):e0153021.","journal-title":"mBio"},{"issue":"4","key":"364_CR10","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/S0021-9258(17)43359-X","volume":"259","author":"M Trudel","year":"1984","unstructured":"Trudel M, Van Genechten T, Meuth M. Biochemical characterization of the hamster thy mutator gene and its revertants. J Biol Chem. 1984;259(4):2355\u20139.","journal-title":"J Biol Chem"},{"issue":"1","key":"364_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13045-022-01263-x","volume":"15","author":"H-l Wu","year":"2022","unstructured":"Wu H-l, Gong Y, Ji P, et al. Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy. J Hematol Oncol. 2022;15(1):45.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"364_CR12","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/ng0493-317","volume":"3","author":"J Whelan","year":"1993","unstructured":"Whelan J, Phear G, Yamauchi M, et al. Clustered base substitutions in CTP synthetase conferring drug resistance in Chinese hamster ovary cells. Nat Genet. 1993;3(4):317\u201322.","journal-title":"Nat Genet"},{"issue":"30","key":"364_CR13","doi-asserted-by":"publisher","first-page":"e2026621118","DOI":"10.1073\/pnas.2026621118","volume":"118","author":"X Zhou","year":"2021","unstructured":"Zhou X, Guo CJ, Chang CC, et al. Structural basis for ligand binding modes of CTP synthase. Proc Natl Acad Sci USA. 2021;118(30):e2026621118.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"364_CR14","doi-asserted-by":"publisher","first-page":"bio050328","DOI":"10.1242\/bio.050328","volume":"9","author":"JC Simonet","year":"2020","unstructured":"Simonet JC, Foster MJ, Lynch EM, et al. CTP synthase polymerization in germline cells of the developing egg supports egg production. Biol Open. 2020;9(7):bio050328.","journal-title":"Biol Open"},{"issue":"5640","key":"364_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/271071a0","volume":"271","author":"JC Williams","year":"1978","unstructured":"Williams JC, Kizaki H, Weber G, et al. Increased CTP synthetase activity in cancer cells. Nature. 1978;271(5640):71\u20133.","journal-title":"Nature"},{"issue":"2","key":"364_CR16","first-page":"915","volume":"20","author":"H Fan","year":"2019","unstructured":"Fan H, Lu S, Wang S, et al. Identification of critical genes associated with human osteosarcoma metastasis based on integrated gene expression profiling. Mol Med Rep. 2019;20(2):915\u201330.","journal-title":"Mol Med Rep"},{"issue":"7504","key":"364_CR17","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/nature13386","volume":"510","author":"E Martin","year":"2014","unstructured":"Martin E, Palmic N, Sanquer S, et al. CTP synthase 1 deficiency in humans reveals its central role in lymphocyte proliferation. Nature. 2014;510(7504):288\u201392.","journal-title":"Nature"},{"issue":"8","key":"364_CR18","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1007\/s10875-016-0332-z","volume":"36","author":"ZY Kucuk","year":"2016","unstructured":"Kucuk ZY, Zhang K, Filipovich L, et al. CTP synthase 1 deficiency in successfully transplanted siblings with combined immune deficiency and chronic active EBV infection. J Clin Immunol. 2016;36(8):750\u20133.","journal-title":"J Clin Immunol"},{"issue":"7","key":"364_CR19","first-page":"675","volume":"6","author":"SL Zaknoen","year":"1992","unstructured":"Zaknoen SL, Christian SL, Suen R, et al. B-chronic lymphocytic leukemia cells contain both endogenous kappa immunoglobulin mRNA and critical immunoglobulin gene activation transcription factors. Leukemia. 1992;6(7):675\u20139.","journal-title":"Leukemia"},{"issue":"2","key":"364_CR20","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/SLA.0000000000003406","volume":"273","author":"L Konczalla","year":"2021","unstructured":"Konczalla L, Ghadban T, Effenberger KE, et al. Prospective comparison of the prognostic relevance of circulating tumor cells in blood and disseminated tumor cells in bone marrow of a single patient\u2019s cohort with esophageal cancer. Ann Surg. 2021;273(2):299\u2013305.","journal-title":"Ann Surg"},{"issue":"11","key":"364_CR21","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/s41419-021-04368-2","volume":"12","author":"Y Han","year":"2021","unstructured":"Han Y, Hu X, Yun X, et al. Nucleolar and spindle associated protein 1 enhances chemoresistance through DNA damage repair pathway in chronic lymphocytic leukemia by binding with RAD51. Cell Death Dis. 2021;12(11):1083.","journal-title":"Cell Death Dis"},{"issue":"18","key":"364_CR22","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","volume":"32","author":"Z Gu","year":"2016","unstructured":"Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics. 2016;32(18):2847\u20139.","journal-title":"Bioinformatics"},{"issue":"1","key":"364_CR23","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/imr.12791","volume":"291","author":"S Latour","year":"2019","unstructured":"Latour S, Fischer A. Signaling pathways involved in the T-cell-mediated immunity against Epstein-Barr virus: lessons from genetic diseases. Immunol Rev. 2019;291(1):174\u201389.","journal-title":"Immunol Rev"},{"issue":"5","key":"364_CR24","doi-asserted-by":"publisher","first-page":"e133880","DOI":"10.1172\/jci.insight.133880","volume":"5","author":"E Martin","year":"2020","unstructured":"Martin E, Minet N, Boschat AC, et al. Impaired lymphocyte function and differentiation in CTPS1-deficient patients result from a hypomorphic homozygous mutation. JCI insight. 2020;5(5):e133880.","journal-title":"JCI insight"},{"issue":"1","key":"364_CR25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12967-021-03206-5","volume":"20","author":"Y Lin","year":"2022","unstructured":"Lin Y, Zhang J, Li Y, et al. CTPS1 promotes malignant progression of triple-negative breast cancer with transcriptional activation by YBX1. J Transl Med. 2022;20(1):17.","journal-title":"J Transl Med"},{"issue":"1","key":"364_CR26","doi-asserted-by":"publisher","first-page":"113337","DOI":"10.1016\/j.yexcr.2022.113337","volume":"420","author":"C Andreadis","year":"2022","unstructured":"Andreadis C, Li T, Liu JL. Ubiquitination regulates cytoophidium assembly in Schizosaccharomyces pombe. Exp Cell Res. 2022;420(1):113337.","journal-title":"Exp Cell Res"},{"issue":"40","key":"364_CR27","doi-asserted-by":"publisher","first-page":"14686","DOI":"10.1074\/jbc.RA119.009913","volume":"294","author":"C Andreadis","year":"2019","unstructured":"Andreadis C, Hulme L, Wensley K, et al. The TOR pathway modulates cytoophidium formation in Schizosaccharomyces pombe. J Biol Chem. 2019;294(40):14686\u2013703.","journal-title":"J Biol Chem"},{"issue":"1","key":"364_CR28","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41594-019-0352-5","volume":"27","author":"L Em","year":"2020","unstructured":"Em L, Jm K. Coupled structural transitions enable highly cooperative regulation of human CTPS2 filaments. Nat Struct Mol Biol. 2020;27(1):42\u20138.","journal-title":"Nat Struct Mol Biol"},{"issue":"44","key":"364_CR29","doi-asserted-by":"publisher","first-page":"33727","DOI":"10.1074\/jbc.M110.178566","volume":"285","author":"KM Kassel","year":"2010","unstructured":"Kassel KM, da Au R, Higgins MJ, et al. Regulation of human cytidine triphosphate synthetase 2 by phosphorylation. J Biol Chem. 2010;285(44):33727\u201336.","journal-title":"J Biol Chem"},{"issue":"6","key":"364_CR30","doi-asserted-by":"publisher","first-page":"599","DOI":"10.4161\/cbt.11.6.14670","volume":"11","author":"WL Tan","year":"2011","unstructured":"Tan WL, Bhattacharya B, Loh M, et al. Low cytosine triphosphate synthase 2 expression renders resistance to 5-fluorouracil in colorectal cancer. Cancer Biol Ther. 2011;11(6):599\u2013608.","journal-title":"Cancer Biol Ther"},{"issue":"7267","key":"364_CR31","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/nature08467","volume":"461","author":"SP Jackson","year":"2009","unstructured":"Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009;461(7267):1071\u20138.","journal-title":"Nature"},{"issue":"1","key":"364_CR32","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40880-018-0313-0","volume":"38","author":"M Zhang","year":"2018","unstructured":"Zhang M, Wang L, An K, et al. Lower genomic stability of induced pluripotent stem cells reflects increased non-homologous end joining. Cancer Commun. 2018;38(1):49.","journal-title":"Cancer Commun"},{"issue":"1","key":"364_CR33","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40164-021-00242-1","volume":"10","author":"M Valikhani","year":"2021","unstructured":"Valikhani M, Rahimian E, Ahmadi SE, et al. Involvement of classic and alternative non-homologous end joining pathways in hematologic malignancies: targeting strategies for treatment. Exp Hematol Oncol. 2021;10(1):51.","journal-title":"Exp Hematol Oncol"},{"issue":"3","key":"364_CR34","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/nrm2858","volume":"11","author":"S Negrini","year":"2010","unstructured":"Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability\u2013an evolving hallmark of cancer. Nat Rev Mol Cell Biol. 2010;11(3):220\u20138.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"364_CR35","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41375-021-01347-6","volume":"36","author":"A Rossi","year":"2022","unstructured":"Rossi A, Orecchioni S, Falvo P, et al. Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma. Leukemia. 2022;36(1):197\u2013209.","journal-title":"Leukemia"},{"issue":"9","key":"364_CR36","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/cac2.12038","volume":"40","author":"D Liu","year":"2020","unstructured":"Liu D, Wu Y. Association of an anaplastic lymphoma kinase pathway signature with cell de-differentiation, neoadjuvant chemotherapy response, and recurrence risk in breast cancer. Cancer Commun. 2020;40(9):422\u201334.","journal-title":"Cancer Commun"},{"issue":"Suppl 1","key":"364_CR37","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/S0140-6736(15)60373-7","volume":"385","author":"M Kwok","year":"2015","unstructured":"Kwok M, Davies N, Agathanggelou A, et al. Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathway. Lancet. 2015;385(Suppl 1):S58.","journal-title":"Lancet"},{"issue":"6","key":"364_CR38","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1158\/0008-5472.CAN-21-1707","volume":"82","author":"Z Sun","year":"2022","unstructured":"Sun Z, Zhang Z, Wang QQ, et al. Combined inactivation of CTPS1 and ATR is synthetically lethal to MYC-overexpressing cancer cells. Cancer Res. 2022;82(6):1013\u201324.","journal-title":"Cancer Res"},{"key":"364_CR39","doi-asserted-by":"publisher","first-page":"16096","DOI":"10.1038\/nrdp.2016.96","volume":"3","author":"TJ Kipps","year":"2017","unstructured":"Kipps TJ, Stevenson FK, Wu CJ, et al. Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017;3:16096.","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"364_CR40","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1002\/ajh.24808","volume":"92","author":"J Crombie","year":"2017","unstructured":"Crombie J, Davids MS. IGHV mutational status testing in chronic lymphocytic leukemia. Am J Hematol. 2017;92(12):1393\u20137.","journal-title":"Am J Hematol"},{"issue":"3\u20134","key":"364_CR41","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3109\/10428190109057924","volume":"40","author":"O Monni","year":"2001","unstructured":"Monni O, Knuutila S. 11q deletions in hematological malignancies. Leuk Lymphoma. 2001;40(3\u20134):259\u201366.","journal-title":"Leuk Lymphoma"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-022-00364-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-022-00364-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-022-00364-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T07:13:23Z","timestamp":1673507603000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-022-00364-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,12]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["364"],"URL":"https:\/\/doi.org\/10.1186\/s40164-022-00364-0","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,12]]},"assertion":[{"value":"13 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was gained from all participants based on guidelines of the Declaration of Helsinki. All experiments were approved by the Medical Ethical Committee of Shandong Provincial Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}